JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB277512

Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1]

Be the first to review this product! Submit a review

|

(2 Publications)

Human Recombinant Monoclonal SPIKE antibody. Suitable for I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2 samples. Cited in 2 publications.

View Alternative Names

2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein

4 Images
Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)
  • I-ELISA

Lab

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)

Indirect competition ELISA showing competitive binding of ab277512 (CV1) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)
  • I-ELISA

Lab

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)

Indirect competition ELISA showing competitive binding of ab277512 (CV1) to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)
  • I-ELISA

Lab

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)

Indirect ELISA showing ab277512 (CV1) binding to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well ab272105 and binding of ab277512 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)
  • I-ELISA

Lab

Indirect ELISA - Anti-SARS-CoV-2 Spike Ectodomain antibody [CV1] (AB277512)

Indirect ELISA showing ab277512 (CV1) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of ab277512 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

Key facts

Host species

Human

Clonality

Monoclonal

Clone number

CV1

Isotype

IgG1

Light chain type

lambda

Carrier free

No

Applications

I-ELISA

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Recombinant full length protein - SARS-CoV-2": { "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>" } } }

Product details

CV1 antibody cross-reacts with SARS-CoV-2 Spike Ectodomain (including S1 domain), but not with SARS-CoV-2 Spike RBD. CV1 does not demonstrate significant neutralising ability in in-direct ELISA, measuring competitive binding of CV1 to SARS-CoV-2 Spike RBD in the presence of human ACE2

Please note: This antibody was first isolated as an IgG1 lambda subclass. During the cloning process for the recombinant product, this was converted to an IgG1 kappa subclass, although the light chain variable region is still of the lambda subclass.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.02% Proclin 300 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Ectodomain often referred to simply as the spike protein is a critical component of the virus that enables entry into host cells. This glycoprotein is about 180 kDa and is prominently expressed on the viral surface. The spike protein is marked by significant regions including the S1 and S2 subunits which facilitate the binding and fusion processes necessary for viral entry into human cells. Variants like the D614G and notable mutations such as H69 deletion or D80A affect its structure. The spike protein is central to vaccine design due to its role in mediating infection.
Biological function summary

The spike protein is critical for the interaction with the host angiotensin-converting enzyme 2 (ACE2) serving as an important component in the viral entry into human cells. It forms a trimeric complex important for mediating the fusion of the viral membrane with the host cell's membrane. Structural changes such as deletions in the HV69-70 region or mutations like D80A can impact the protein's functionality and viral virulence. Therefore understanding these mutations has implications for infection control efforts.

Pathways

The spike protein plays a central role in the viral invasion pathway that starts with the recognition of the ACE2 receptor on the host cell. This pathway integrates the spike protein's functionality with other viral and host proteins leading to cell entry and subsequent viral replication. The renin-angiotensin system (RAS) is closely related given the ACE2 receptor's involvement in this physiological pathway highlighting the importance of these interactions in both viral pathology and host response.

The spike protein is instrumental in the pathogenesis of COVID-19 and related respiratory disorders. Its interaction with ACE2 is central in determining the infection's severity and transmission potential. Additionally the spike protein's structural changes such as HV69-70 deletions or D80A mutations can alter the disease manifestation by affecting how the immune system recognizes the virus. This structural variability potentially impacts vaccine efficacy and therapeutic antibody effectiveness complicating disease management and treatment strategies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
See full target information S

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Lab on a chip 25:5292-5301 PubMed40878245

2025

Benchmarking microfluidic and immunomagnetic platforms for isolating circulating tumor cells in pancreatic cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Celine Macaraniag,Ifra Khan,Alexandra Barabanova,Valentina Valle,Jian Zhou,Pier C Giulianotti,Alain Borgeat,Gina Votta-Velis,Ian Papautsky

Molecular therapy. Methods & clinical development 24:355-366 PubMed35127966

2022

Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2.

Applications

Unspecified application

Species

Unspecified reactive species

Tristan A Scott,Aroon Supramaniam,Adi Idris,Angelo A Cardoso,Surya Shrivastava,Gabrielle Kelly,Nicole A Grepo,Citradewi Soemardy,Roslyn M Ray,Nigel A J McMillan,Kevin V Morris
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com